CureVac trials add questions for mRNA vaccines

Following the success stories of the Pfizer and Moderna mRNA vaccines for COVID-19, many thought mRNA vaccines paved the way for the future of immunisation. These theories may be faced with a setback as phase-III trials of fellow mRNA vaccine candidate CureVac has achieved subpar results. CureVac, based in Tübingen, Germany, announced data from the …

CureVac trials add questions for mRNA vaccines Read More »